# The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2022 · $400,000

## Abstract

With the evolution of the Experimental Therapeutics Clinical Trials Network (ETCTN), the Johns Hopkins
Translational Science Team (JHTST) expanded in 2019 by bringing 8 Affiliate Organizations (AO) under our
Lead Academic Organization (LAO) with the goal to enhance and accelerate our collective contribution to the
drug development efforts of the NCI. We have organized a comprehensive and cohesive infrastructure that can
conduct high-quality clinical trials evaluating novel anticancer agents, in combinations, in molecularly selected
patient populations, or rare tumor sites. Our infrastructure stems from the need to be clinically efficient,
regulatory compliant and scientifically rigorous in our approach as we collaborate as network members within
the ETCTN. With the submission of this administrative supplement, our infrastructure will now consist of nine
experienced NCI-designated Cancer Centers: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,
Emory Winship Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Memorial Sloan
Kettering Cancer Center, University of Virginia Cancer Center, University of Wisconsin Carbone Cancer
Center, University of Colorado Comprehensive Cancer Center, The University of Maryland Greenebaum
Cancer Center, and Wake Forest Baptist Comprehensive Cancer Center (the newest and focus of this
supplement). This collection of Centers brings together many unique discovery strengths, diverse patient
volumes, and locations both urban and rural. We will focus on 5 Specific Aims: Aim 1- To lead and maintain a
clinical trial consortium that will support cancer clinical trials from Phase 1 initiation through proof-of-activity
and foster seamless Phase 2 clinical development of NCI CTEP IND agents; Aim 2- To actively participate and
engage disease-focused clinical investigators in the ETCTN by promoting accrual to a range of ETCTN studies
led by other LAO/AO members; Aim 3- To incorporate and implement innovative correlative and biological
laboratory studies in the context of or as eligibility for participation in early phase clinical studies that enhance
our understanding of determinants of toxicity and response that will be used for further definitive practice-
changing clinical trial evaluation; Aim 4- To train the next generation of investigators in drug development; and
Aim 5- To promote diversity and inclusion of underserved/minority participants on ETCTN trials. With 9 Centers
within our Consortium, we anticipate little problem in meeting the grant metrics of 100 accruals per year,
submitting up to 8 LOI concepts/year to have at least 2 new studies approved each year, functioning as a
network by having Disease-Focused Clinical Investigators champion ETCTN studies at each Site across
disease sites, and to provide opportunities to engage and train early career investigators in drug development.
We anticipate that our contributions within the ETCTN will impact the clinical care of cancer patients.

## Key facts

- **NIH application ID:** 10677365
- **Project number:** 3UM1CA186691-06S3
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Michael A Carducci
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $400,000
- **Award type:** 3
- **Project period:** 2022-09-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10677365

## Citation

> US National Institutes of Health, RePORTER application 10677365, The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies (3UM1CA186691-06S3). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10677365. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*